#Sustainability #USA #Zentiva #Public Health #Prague

Zentiva's Commitment to Sustainability

Zentiva has released its much-anticipated 2025 Sustainability Report, illustrating a milestone year of progress in areas critical to public health, environmental protection, and responsible business practices. The report serves as a testament to the company’s belief that corporate growth can occur hand in hand with environmental responsibility.

Key Highlights of the 2025 Sustainability Report

In 2025, Zentiva achieved a notable 10% reduction in Scope 1 and Scope 2 emissions within its operations while simultaneously increasing its net revenue and EBITDA. This remarkable achievement was recognized by the Science Based Targets initiative (SBTi), which validated the company’s short and long-term targets including a commitment to reduce Scope 1, Scope 2, and Scope 3 emissions by 63% by 2034, and aims for a net-zero reduction by 2050.

Among the significant accomplishments reported in 2025:

• - Renewable Energy Usage: 83% of the electricity consumed within Zentiva's operations is now sourced from renewable resources, with 100% in its EU manufacturing plants.
• - Water Conservation: The quantity of recycled and reused water has nearly doubled between 2021 and 2025.
• - Waste Management: 47% of waste is no longer discarded but is either reused, recycled, or repurposed, showcasing a strong commitment to reducing landfill contributions.
• - Biodiversity Initiatives: Over 130,000 trees have been planted to support reforestation efforts, alongside the adoption of 3.5 million bees through Zentiva initiatives to promote biodiversity.
• - Community Engagement: The company has conducted more than 120 human and community projects across Europe and India under its initiative #WeHelpOthers.

Industry Recognition and Awards

Zentiva’s sustainability initiatives have not gone without notice. The company was bestowed with a Gold Medal by EcoVadis, positioning its sustainability program among the top 2% of the pharmaceutical industry. Furthermore, it received the Transparency Award 2025 from EUPD Group for its excellent reporting and communication regarding sustainability.

Steffen Saltofte, CEO of Zentiva, emphasized the company's responsibility in supporting public health systems while reducing ecological impacts. "Every day, millions rely on the accessibility, affordability, and availability of the medications we produce and deliver."

Ines Windisch, Head of Corporate Affairs and Sustainability, added, "The sustainability report illustrates how our daily actions contribute to a healthier society and environment. Protecting people and the planet is a commitment that needs constant attention in all our endeavors."

A Continuous Commitment to Access and Affordability

As a key player in the European market for off-patent medicines, Zentiva is vital in ensuring public access to quality and affordable medications. Currently, off-patent medicines represent approximately 70% of all prescriptions but account for only 19% of total medicine expenditures. This makes them essential for the affordability and sustainability of public health systems as highlighted by IQVIA in 2024.

Zentiva plans to continue investing in its production capabilities and sustainability strategy to guarantee that patients maintain access to the medications they need, both now and in the future.

The full content of the Zentiva 2025 Sustainability Report can be accessed at www.zentiva.com/sustainability.

About Zentiva

Zentiva is dedicated to promoting health and well-being for all generations by developing, manufacturing, and providing high-quality, affordable medicines to over 100 million people across 40 countries in Europe. With four production facilities and an extensive network of external manufacturing partners, Zentiva supports supply security and employs over 5,400 talented individuals in more than 30 countries, united in the commitment to support those reliant on its products. For more information, visit www.zentiva.com.